- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01434485
Nexium Capsules Clinical Experience Investigation
April 14, 2014 updated by: AstraZeneca
The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy of Nexium capsules in daily clinical usage for the patients who have been prescribed Nexium for "gastric ulcer", "duodenal ulcer", "anastomotic ulcer", "reflux oesophagitis", "non-erosive reflux disease", or "Zollinger-Ellison syndrome"
Study Overview
Status
Completed
Detailed Description
Nexium capsules Clinical Experience Investigation
Study Type
Observational
Enrollment (Actual)
3691
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aichi, Japan
- Research Site
-
Akita, Japan
- Research Site
-
Aomori, Japan
- Research Site
-
Chiba, Japan
- Research Site
-
Ehime, Japan
- Research Site
-
Fukui, Japan
- Research Site
-
Fukuoka, Japan
- Research Site
-
Fukushima, Japan
- Research Site
-
Gifu, Japan
- Research Site
-
Gunma, Japan
- Research Site
-
Hiroshima, Japan
- Research Site
-
Hokkaido, Japan
- Research Site
-
Hyogo, Japan
- Research Site
-
Ibaraki, Japan
- Research Site
-
Ishikawa, Japan
- Research Site
-
Iwate, Japan
- Research Site
-
Kagawa, Japan
- Research Site
-
Kagoshima, Japan
- Research Site
-
Kanagawa, Japan
- Research Site
-
Kochi, Japan
- Research Site
-
Kumamoto, Japan
- Research Site
-
Kyoto, Japan
- Research Site
-
Mie, Japan
- Research Site
-
Miyagi, Japan
- Research Site
-
Miyazaki, Japan
- Research Site
-
Nagano, Japan
- Research Site
-
Nagasaki, Japan
- Research Site
-
Nara, Japan
- Research Site
-
Niigata, Japan
- Research Site
-
Oita, Japan
- Research Site
-
Okayama, Japan
- Research Site
-
Okinawa, Japan
- Research Site
-
Osaka, Japan
- Research Site
-
Saga, Japan
- Research Site
-
Saitama, Japan
- Research Site
-
Shiga, Japan
- Research Site
-
Shimane, Japan
- Research Site
-
Shizuoka, Japan
- Research Site
-
Tochigi, Japan
- Research Site
-
Tokushima, Japan
- Research Site
-
Tokyo, Japan
- Research Site
-
Tottori, Japan
- Research Site
-
Toyama, Japan
- Research Site
-
Wakayama, Japan
- Research Site
-
Yamagata, Japan
- Research Site
-
Yamaguchi, Japan
- Research Site
-
Yamanashi, Japan
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients treated with Nexium for the first time due to gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux oesophagitis, non-erosive reflux disease, Zollinger-Ellison syndrome.
Description
Inclusion Criteria: - Patients treated with Nexium for the first time due to gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux oesophagitis, non-erosive reflux disease, Zollinger-Ellison syndrome.
Exclusion Criteria: - None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Nexium
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Adverse Drug Reactions
Time Frame: Patients with gastric ulcer, anastomotic ulcer or Zollinger-Ellison syndrome: 8 weeks
|
Patients with gastric ulcer, anastomotic ulcer or Zollinger-Ellison syndrome: 8 weeks
|
Number of Adverse Drug Reactions
Time Frame: Patients with duodenal ulcer: 6 weeks
|
Patients with duodenal ulcer: 6 weeks
|
Number of Adverse Drug Reactions
Time Frame: Patients with reflux oesophagitis: 8 weeks
|
Patients with reflux oesophagitis: 8 weeks
|
Number of Adverse Drug Reactions
Time Frame: Patients with non-erosive reflux disease: 4 weeks
|
Patients with non-erosive reflux disease: 4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (Actual)
March 1, 2014
Study Completion (Actual)
March 1, 2014
Study Registration Dates
First Submitted
September 14, 2011
First Submitted That Met QC Criteria
September 14, 2011
First Posted (Estimate)
September 15, 2011
Study Record Updates
Last Update Posted (Estimate)
April 16, 2014
Last Update Submitted That Met QC Criteria
April 14, 2014
Last Verified
April 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Endocrine Gland Neoplasms
- Gastroenteritis
- Intestinal Diseases
- Esophageal Motility Disorders
- Deglutition Disorders
- Esophageal Diseases
- Peptic Ulcer
- Duodenal Diseases
- Pancreatic Diseases
- Paraneoplastic Syndromes
- Pancreatic Neoplasms
- Carcinoma, Islet Cell
- Paraneoplastic Endocrine Syndromes
- Ulcer
- Gastroesophageal Reflux
- Esophagitis, Peptic
- Stomach Ulcer
- Duodenal Ulcer
- Esophagitis
- Gastrinoma
- Zollinger-Ellison Syndrome
Other Study ID Numbers
- D961HC00010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison Syndrome
-
AstraZenecaCompletedZollinger-Ellison Syndrome | Reflux Esophagitis (RE) | Gastric Ulcer (GU) | Duodenal Ulcer (DU) | Anastomotic Ulcer (AU) | Non-erosive Reflux Esophagitis Disease (NERD)Japan
-
TakedaCompletedGastric Ulcer, Duodenal Ulcer, and Reflux EsophagitisJapan
-
AstraZenecaCompletedGastric Ulcer | Duodenal Ulcer | Reflux Esophagitis | Anastomotic Ulcer | Etc.Japan
-
Daewoong Pharmaceutical Co. LTD.RecruitingNon-erosive Reflux Disease | Non-Erosive Gastro-Esophageal Reflux Disease | Non-Erosive Esophageal Reflux DiseaseKorea, Republic of
-
AstraZenecaCompletedGastric Ulcer | Duodenal Ulcer | Reflux EsophagitisJapan
-
Federal State Budgetary Scientific Institution...RecruitingGastroesophageal Reflux Disease | GERD | Non-erosive Reflux Disease | Erosive Esophagitis | Non-Erosive Gastro-Esophageal Reflux Disease | Gastroesophageal ErosionRussian Federation
-
Private Healthcare Institution Clinical Hospital...RecruitingBile Reflux | Ulcer, GastricRussian Federation
-
Trio Medicines Ltd.Ferring PharmaceuticalsCompletedReflux OesophagitisUnited Kingdom
-
Trio Medicines Ltd.Ferring PharmaceuticalsCompletedReflux OesophagitisUnited Kingdom
-
Trio Medicines Ltd.Ferring PharmaceuticalsCompletedReflux OesophagitisUnited Kingdom